In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them?

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CMEs: Quick Take Vol. 78
• Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial

In this episode, we explore the treatment algorithm for adult ADHD with Dr. Oscar Bukstein from Harvard Medical School. Should you start with stimulants or non-stimulants when substance use disorder complicates the picture? Discover how comorbidities like depression and anxiety reshape your medication selection strategy for optimal patient outcomes.

Faculty: Oscar G. Bukstein, M.D., M.P.H Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide
• Treatment Algorithm for Adult ADHD

In this episode, we explore pramipexole—a Parkinson's medication—as a promising add-on treatment for treatment-resistant bipolar depression. Could a dopamine agonist be the unexpected solution when standard mood stabilizers and antipsychotics fail? We examine the PAX-BD trial's findings, safety concerns, and practical clinical applications.

Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 78
• Treatment-Resistant Bipolar Depression: Is Adjunctive Pramipexole An Option?

In this episode, we explore the controversial role of SERT gene testing in predicting SSRI response with Dr. Chris Aiken. Can genetic testing really tell us which patients will respond to antidepressants, or are we putting too much faith in pharmacogenetic promises that lack solid evidence?

Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
• SERT Gene and SSRI Response: Is It Clinically Useful?

In this episode, we explore a critical drug interaction: SSRIs combined with anticoagulants increase major bleeding risk by 35-47%. Should age and sex change our prescribing decisions? We break down the evidence from nearly 100,000 patients and discuss safer antidepressant alternatives for high-risk individuals.

Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CME: Quick Take Vol. 77
• Do SSRIs Increase Major Bleeding Risk with Oral Anticoagulants?

In this episode, we explore the paradox of pharmacogenetic testing with Dr. Chris Aiken: why do these tests consistently fail in clinical trials despite showing promise in understanding drug metabolism? Could industry bias and statistical noise be masking the truth about personalized psychiatric medicine?

Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
• Pharmacogenetic Panels: Do They Really Work?

In this episode, we explore how Lurasidone at lower doses (20-60 mg/day) effectively treats both depression and anxiety in bipolar I disorder. Why does the lower dose range outperform higher doses for patients with severe anxiety? Discover the surprising dose-dependent effects and metabolic advantages that make this a game-changer.

Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here.
• Earn 0.75 CMEs: Quick Take Vol. 77
• Is Lurasidone Effective for Bipolar Depression with Comorbid Anxiety?

In this episode, we explore how GLP-1 agonists—the weight loss medications making headlines everywhere—could revolutionize management of antipsychotic-induced weight gain. Can these drugs help patients lose weight while maintaining psychiatric stability? We examine the latest evidence and discuss practical implementation strategies for your practice.

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 76
• Antipsychotic-Induced Weight Gain: Are GLP-1 Agonists Effective?

In this episode, we explore pharmacogenetics-guided dosing strategies with Dr. Chris Aiken. What if your patient's treatment failure isn't about the wrong medication, but the wrong dose? Discover how genetic testing reveals whether patients are poor or rapid metabolizers and learn the specific dosing adjustments that can transform outcomes.

Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
• Pharmacogenetics-Guided Dosing: Strategies for Poor and Rapid Metabolizers

In this episode, we explore the newly published INTEGRATE guidelines—the first truly international algorithm for schizophrenia treatment. Should clozapine be started after just 12 weeks? When are long-acting injectables appropriate for first-episode patients? Discover how these guidelines aim to standardize quality care worldwide.

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CME: Quick Take Vol. 77
• INTEGRATE: New Schizophrenia Treatment Guidelines